(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are AUREA, OCI, and BEAULIEU-AV. CERT.

The three biggest losers today are MITHRA, PETROLIA, and BORGESTAD.

Winners today

1. AUREA (AURE.PA)

8.98% Price Change

Aurea SA engages in the recycling of black motor oil in France. The company is also involved in the manufacturing of remold tires from used tires and recycling rigid PVC. It recycles plastics and packaging products; refines and recycles aluminum; recycles copper and produces copper alloys; and treats and recycles zinc, lead, and cadmium. In addition, the comany engages in the treatment and decontamination of mercury waste. The company was formerly known as AUER and changed its name to Aurea SA in 1988. Aurea SA is based in Paris, France.

CAC 40 ended the session with AUREA rising 8.98% to €5.34 on Friday while CAC 40 rose 0.26% to €7,135.06.

Earnings Per Share

As for profitability, AUREA has a trailing twelve months EPS of €0.33.

PE Ratio

AUREA has a trailing twelve months price to earnings ratio of 16.18. Meaning, the purchaser of the share is investing €16.18 for every euro of annual earnings.

Volatility

AUREA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.36%, a negative 1.28%, and a positive 2.13%.

AUREA’s highest amplitude of average volatility was 5.64% (last week), 3.04% (last month), and 2.13% (last quarter).

Volume

Today’s last reported volume for AUREA is 3531 which is 90.65% above its average volume of 1852.

More news about AUREA.

2. OCI (OCI.AS)

8.96% Price Change

OCI N.V. produces and distributes hydrogen-based and natural gas-based products to agricultural, transportation, and industrial customers. It operates through Methanol US, Methanol Europe, Nitrogen US, Nitrogen Europe, and Fertiglobe segments. The company offers anhydrous ammonia, granular urea, urea ammonium nitrate solution, calcium ammonium nitrate, ammonium sulphate, aqueous ammonia, nitric acid, urea solution, bio-methanol, methanol, melamine, and diesel exhaust fluid, as well as other nitrogen products. It also owns and operates an ammonia terminal at the port of Rotterdam. The company has operations in Europe, the Americas, the Middle East, Africa, Asia, and Oceania. OCI N.V. has a strategic partnership with Abu Dhabi National Oil Company. OCI N.V. was founded in 2013 and is headquartered in Amsterdam, the Netherlands.

AEX-Index ended the session with OCI rising 8.96% to €26.99 on Friday, following the last session’s downward trend. AEX-Index rose 0.39% to €728.79, after two consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, OCI has a trailing twelve months EPS of €0.84.

PE Ratio

OCI has a trailing twelve months price to earnings ratio of 32.13. Meaning, the purchaser of the share is investing €32.13 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.07%.

More news about OCI.

3. BEAULIEU-AV. CERT (BEAB.BR)

8.82% Price Change

Immo-Beaulieu NV owns and operates real estate properties. The company is based in Brussels, Belgium. Immo-Beaulieu NV operates as a subsidiary of KBC Bank NV.

BEL 20 ended the session with BEAULIEU-AV. CERT rising 8.82% to €4.44 on Friday while BEL 20 rose 0.94% to €3,553.01.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BEAULIEU-AV. CERT’s stock is considered to be overbought (>=80).

More news about BEAULIEU-AV. CERT.

4. AB SCIENCE (AB.PA)

8.31% Price Change

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

CAC 40 ended the session with AB SCIENCE jumping 8.31% to €2.41 on Friday, following the last session’s downward trend. CAC 40 rose 0.26% to €7,135.06, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, AB SCIENCE has a trailing twelve months EPS of €-0.26.

More news about AB SCIENCE.

5. NEW SOURCES ENERGY (NSE.AS)

7.69% Price Change

New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.

AEX-Index ended the session with NEW SOURCES ENERGY rising 7.69% to €0.04 on Friday, after two sequential sessions in a row of losses. AEX-Index jumped 0.39% to €728.79, after two successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -288.52%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEW SOURCES ENERGY’s stock is considered to be overbought (>=80).

More news about NEW SOURCES ENERGY.

6. VOW (VOW.OL)

6.02% Price Change

Vow ASA, together with its subsidiaries, produces, delivers, and maintains systems for processing and purifying wastewater, food waste, solid waste, and bio sludge in Norway, France, Poland, the United States, and Italy. It operates in three segments: Projects Cruise, Aftersales, and Landbased. The Projects Cruise segment delivers ship systems to shipyards for newbuild constructions, which include advanced wastewater purification, waste management, and food waste processing; and advanced systems to shipowners for ships. The Aftersales segment provides spare parts and consumables; chemicals; and tailor-made service and maintenance programs. The Landbased segment offers Biogreen, a patented pyrolysis process for converting biomass, plastics, and waste into energy; Safesteril, a patented sterilisation process for food and pharmaceutical ingredients; and industrial robotics solutions, including robotic systems for waste recycling processes. This segment also develops, designs, and fabricates industrial furnaces and equipment for heat treatment processes. The company serves cruise, aquaculture, and landbased industries, as well as utilities. It has a strategic partnership agreement with Repsol, S.A. to explore applications and solutions to produce clean and renewable energy for CO2 emission reduction; European Tyre Enterprise Ltd. to develop a modularised and industrial solutions, and value chain to turn end-of-life tires into raw material and renewable energy; GRTgaz to produce a demo plant built to confirm that CO2 neutral pyrolysis gas can replace fossil gas in the European gas grid; SAS IMPROVE to develop technological solutions for the farm to fork valorisation of future proteins; and Imtech Steri's Biosteam to offer a range of ingredient sterilisation solutions and services. The company was formerly known as Scanship Holding ASA and changed its name to VOW ASA in January 2020. Vow ASA was founded in 2011 and is headquartered in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with VOW rising 6.02% to €14.10 on Friday while Oslo Børs Benchmark Index_GI rose 0.15% to €1,290.99.

Earnings Per Share

As for profitability, VOW has a trailing twelve months EPS of kr0.05.

PE Ratio

VOW has a trailing twelve months price to earnings ratio of 282. Meaning, the purchaser of the share is investing kr282 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.13%.

Volatility

VOW’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.75%, a positive 0.03%, and a positive 2.64%.

VOW’s highest amplitude of average volatility was 2.40% (last week), 1.98% (last month), and 2.64% (last quarter).

More news about VOW.

7. AKER HORIZONS (AKH.OL)

5.94% Price Change

Aker Horizons ASA, through its subsidiaries, develops and invests in a portfolio of companies in the renewable energy and green technology comprising private and public companies worldwide. It sources, develops, structures, builds, and operates wind and solar power assets; and develops, builds, owns, and operates clean hydrogen production at industrial scale. The company also provides products, technology, and solutions within the field of carbon capture, utilization, and storage. In addition, it offers products and services to the hydropower industry; designs and delivers superconducting systems; and produces silicon materials. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Horizons ASA is a subsidiary of Aker Capital AS.

Oslo Børs Benchmark Index_GI ended the session with AKER HORIZONS rising 5.94% to €4.60 on Friday while Oslo Børs Benchmark Index_GI rose 0.15% to €1,290.99.

Earnings Per Share

As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-9.87.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.14%.

More news about AKER HORIZONS.

8. POSTNL (PNL.AS)

5.9% Price Change

PostNL N.V. provides postal and logistics services to businesses and consumers in the Netherlands, rest of Europe, and internationally. The company operates in two segments, Parcels and Mail in the Netherlands; and PostNL Other. It collects, sorts, transports, and delivers letters and parcels; and offers data management, direct marketing, and fulfillment services, as well as cross-border mail and parcels solutions. The company was formerly known as TNT N.V. and changed its name to PostNL N.V. in May 2011. PostNL N.V. is headquartered in the Hague, the Netherlands.

AEX-Index ended the session with POSTNL rising 5.9% to €2.07 on Friday, after three consecutive sessions in a row of losses. AEX-Index rose 0.39% to €728.79, after two sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, POSTNL has a trailing twelve months EPS of €-1.98.

Volatility

POSTNL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.63%, a negative 0.29%, and a positive 1.31%.

POSTNL’s highest amplitude of average volatility was 1.80% (last week), 1.44% (last month), and 1.31% (last quarter).

More news about POSTNL.

9. ADOCIA (ADOC.PA)

5.89% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA jumping 5.89% to €7.37 on Friday while CAC 40 rose 0.26% to €7,135.06.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-2.54.

Moving Average

ADOCIA’s value is way higher than its 50-day moving average of €4.06 and way higher than its 200-day moving average of €3.59.

Yearly Top and Bottom Value

ADOCIA’s stock is valued at €7.37 at 22:40 EST, way above its 52-week high of €6.62.

More news about ADOCIA.

10. ARAMIS GROUP (ARAMI.PA)

5.86% Price Change

Aramis Group SAS engages in the online sale of used cars in Europe. The company operates Aramisauto, Cardoen, and Clicars brands in France, Belgium, and Spain, as well as CarSupermarket platform in the United Kingdom. Aramis Group SAS was founded in 2001 and is based in Arcueil, France.

CAC 40 ended the session with ARAMIS GROUP rising 5.86% to €4.25 on Friday, following the last session’s downward trend. CAC 40 rose 0.26% to €7,135.06, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, ARAMIS GROUP has a trailing twelve months EPS of €-0.63.

More news about ARAMIS GROUP.

Losers Today

1. MITHRA (MITRA.BR)

-12.32% Price Change

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

BEL 20 ended the session with MITHRA sliding 12.32% to €1.42 on Friday while BEL 20 rose 0.94% to €3,553.01.

Earnings Per Share

As for profitability, MITHRA has a trailing twelve months EPS of €-0.99.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -176.58%.

Volatility

MITHRA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 7.95%, a negative 1.47%, and a positive 5.27%.

MITHRA’s highest amplitude of average volatility was 9.19% (last week), 3.99% (last month), and 5.27% (last quarter).

Yearly Top and Bottom Value

MITHRA’s stock is valued at €1.42 at 22:40 EST, way below its 52-week high of €6.87 and way above its 52-week low of €1.25.

More news about MITHRA.

2. PETROLIA (PSE.OL)

-7.02% Price Change

Petrolia SE, together with its subsidiaries, sells and rents energy service equipment to energy industry in Norway, rest of Europe, Asia, and Australia. It operates through two segments, Energy and Energy Service. The company engages in the exploration and production of oil and gas, as well as produces hydrogen and ammonia. It also offers drill pipes, test strings and tubing, and other equipment, as well as casing, handling, and auxiliary tools; and equipment inspection and maintenance services. In addition, the company offers casing and tubing running, drilling, and make and brake services. It serves energy companies, drilling contractors, and energy service companies. The company was formerly known as Petrolia E&P Holdings SE and changed its name to Petrolia SE in January 2013. Petrolia SE was founded in 1997 and is based in Limassol, Cyprus.

Oslo Børs Benchmark Index_GI ended the session with PETROLIA sliding 7.02% to €4.37 on Friday while Oslo Børs Benchmark Index_GI rose 0.15% to €1,290.99.

Earnings Per Share

As for profitability, PETROLIA has a trailing twelve months EPS of kr0.04.

PE Ratio

PETROLIA has a trailing twelve months price to earnings ratio of 109.25. Meaning, the purchaser of the share is investing kr109.25 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.94%.

Volatility

PETROLIA’s last week, last month’s, and last quarter’s current intraday variation average was 2.57%, 0.50%, and 3.39%.

PETROLIA’s highest amplitude of average volatility was 5.71% (last week), 3.70% (last month), and 3.39% (last quarter).

More news about PETROLIA.

3. BORGESTAD (BOR.OL)

-6.85% Price Change

Borgestad ASA develops, manufactures, distributes, and installs refractory products in Norway. The company also develops and manages real estate properties. Its properties include Agora Bytom, a shopping center with a gross area of 52,000 square meters and a rental area of approximately 30,000 square meters, as well as a parking garage with 820 parking lots in Poland. Borgestad ASA was founded in 1904 and is headquartered in Skien, Norway.

Oslo Børs Benchmark Index_GI ended the session with BORGESTAD dropping 6.85% to €1.36 on Friday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.15% to €1,290.99, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, BORGESTAD has a trailing twelve months EPS of kr-0.81.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.11%.

Yearly Top and Bottom Value

BORGESTAD’s stock is valued at kr1.36 at 22:40 EST, way under its 52-week high of kr2.02 and way above its 52-week low of kr1.23.

Volume

Today’s last reported volume for BORGESTAD is 16000 which is 61.58% below its average volume of 41649.

More news about BORGESTAD.

4. ARTEA (ARTE.PA)

-6% Price Change

Artea SA operates as a real estate development company in France. It develops tertiary parks, emblematic projects, urban office buildings, eco-neighborhoods, hotels, shops, and housing projects. The company also generates and supplies electrical power using renewable sources, such as photovoltaics and hydraulics. Artea SA was founded in 2001 and is headquartered in Paris, France.

CAC 40 ended the session with ARTEA dropping 6% to €18.80 on Friday, following the last session’s downward trend. CAC 40 rose 0.26% to €7,135.06, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, ARTEA has a trailing twelve months EPS of €1.47.

PE Ratio

ARTEA has a trailing twelve months price to earnings ratio of 12.79. Meaning, the purchaser of the share is investing €12.79 for every euro of annual earnings.

More news about ARTEA.

5. HOFSETH BIOCARE (HBC.OL)

-5.9% Price Change

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE dropping 5.9% to €2.71 on Friday while Oslo Børs Benchmark Index_GI rose 0.15% to €1,290.99.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.26.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.36%.

More news about HOFSETH BIOCARE.

6. ADUX (ADUX.PA)

-4.96% Price Change

AdUX SA provides advertising services in France, Belgium, Italy, Spain, Germany, the Netherlands, and internationally. It provides non-intrusive advertising, in-content advertising, brand content, and geomarketing services. The company was founded in 1996 and is headquartered in Paris, France.

CAC 40 ended the session with ADUX dropping 4.96% to €1.15 on Friday while CAC 40 jumped 0.26% to €7,135.06.

Earnings Per Share

As for profitability, ADUX has a trailing twelve months EPS of €0.75.

PE Ratio

ADUX has a trailing twelve months price to earnings ratio of 1.53. Meaning, the purchaser of the share is investing €1.53 for every euro of annual earnings.

Volatility

ADUX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.10%, a negative 0.86%, and a positive 2.13%.

ADUX’s highest amplitude of average volatility was 3.38% (last week), 2.91% (last month), and 2.13% (last quarter).

Moving Average

ADUX’s worth is way below its 50-day moving average of €1.41 and way below its 200-day moving average of €1.48.

More news about ADUX.

7. ATENOR (ATEB.BR)

-4.76% Price Change

Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.

BEL 20 ended the session with ATENOR falling 4.76% to €12.00 on Friday, after five sequential sessions in a row of losses. BEL 20 jumped 0.94% to €3,553.01, after five successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, ATENOR has a trailing twelve months EPS of €-9.45.

Volume

Today’s last reported volume for ATENOR is 14088 which is 223.86% above its average volume of 4350.

More news about ATENOR.

8. EQVA (EQVA.OL)

-4.56% Price Change

Eqva ASA, a knowledge-based maritime company, primarily engages in the shipbuilding business worldwide. It operates in two segments, Shipbuilding Technology and Other. The company provides newbuilding, rebuilding, and service assignments on vessels for offshore oil production, renewable energy production, fishing, and fish farming for ship owners. It delivers technology for customers within the seafood, energy, and transport sectors. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was founded in 1999 and is headquartered in Fosnavåg, Norway.

Oslo Børs Benchmark Index_GI ended the session with EQVA sliding 4.56% to €2.72 on Friday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI jumped 0.15% to €1,290.99, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, EQVA has a trailing twelve months EPS of kr-0.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.45%.

Moving Average

EQVA’s worth is under its 50-day moving average of kr2.92 and way below its 200-day moving average of kr3.07.

Volume

Today’s last reported volume for EQVA is 13348 which is 3.34% above its average volume of 12916.

Revenue Growth

Year-on-year quarterly revenue growth grew by 209.8%, now sitting on 594.65M for the twelve trailing months.

More news about EQVA.

9. HYDRATEC (HYDRA.AS)

-3.93% Price Change

Hydratec Industries NV, through its subsidiaries, engages in the manufacture and sale of industrial systems and plastic components for food, health, and mobility markets in the Netherlands, rest of Europe, Asia, North America, South America, Africa, and Oceania. It develops and produces sterilized product handling systems; and automated packaging solutions, including packaging for sterilized food in pouches, tins, and jars, as well as main-meal salads and agri-food in bags, nets, boxes, and crates. The company also supplies industrial incubators to produce day-old chicks; hatchery automation systems for processing of hatchery eggs and day-old chicks; climate control equipment for air and water treatment; hatchery management software for monitoring, analyzing, and optimizing the hatching process; and service and support for hatchery systems operation. In addition, it manufactures extrusion machines for PVC, PVC-O, and PO pipes; plastic injection molding products for use in climate control systems, lorries, bicycle parts, and coffee machines; rubber and plastic precision components for fuel systems, braking and drive systems, dosing systems for beer, coffee and milk, medical cartridges, point-of-care instruments, and diagnosis equipment. Hydratec Industries NV is headquartered in Amersfoort, the Netherlands.

AEX-Index ended the session with HYDRATEC sliding 3.93% to €85.50 on Friday, following the last session’s downward trend. AEX-Index jumped 0.39% to €728.79, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, HYDRATEC has a trailing twelve months EPS of €11.85.

PE Ratio

HYDRATEC has a trailing twelve months price to earnings ratio of 7.22. Meaning, the purchaser of the share is investing €7.22 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.49%.

Volume

Today’s last reported volume for HYDRATEC is 28 which is 67.81% below its average volume of 87.

Volatility

HYDRATEC’s last week, last month’s, and last quarter’s current intraday variation average was 2.30%, 0.19%, and 1.77%.

HYDRATEC’s highest amplitude of average volatility was 2.30% (last week), 1.35% (last month), and 1.77% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HYDRATEC’s stock is considered to be oversold (<=20).

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on May 19, 2023, the estimated forward annual dividend rate is 6 and the estimated forward annual dividend yield is 6.98%.

More news about HYDRATEC.

10. BIOSENIC (BIOS.BR)

-3.88% Price Change

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with BIOSENIC sliding 3.88% to €0.11 on Friday while BEL 20 rose 0.94% to €3,553.01.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.03.

Volume

Today’s last reported volume for BIOSENIC is 346193 which is 68.16% below its average volume of 1087360.

More news about BIOSENIC.

Stay up to date with our winners and losers daily report